Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Holly Meany, MD
Children's National Research Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Children'S National Medical Center
Washington D.C., District of Columbia, United States
- National Cancer Institute
Bethesda, Maryland, United States
- Children'S Hospital Boston/dana-Farber Cancer Institute
Boston, Massachusetts, United States
- the Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2011
- Primary completion
- 31 Jan 2015
- Completion
- 31 Jan 2015
- Last update posted
- 27 Feb 2015
- Registered enrollment
- 17
- Registry id
- NCT01518413
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.